The disclosure concerns novel use of diterpene compound as a therapeutic agent
of inlfammation, immune disease or cancer. More particularly, the present invention
relates to novel use of diterpene compound that include kamebanin, kamebacetal
A, kamebakaurin, and exisanin A, which would be effective for the treatment inflammation,
immune disease or cancer by inhibiting the production of nitric oxide, prostaglandin,
and TNF-a1 through the suppression of NF-k B activity.
